News

Janssen Pharmaceuticals, Inc. announced it has collaborated with Premier Inc. on the first and largest study of its kind to address an unmet medical need for hospitalized patients with atrial fibrillation (AF) who are at risk for ischemic...

Espero Pharmaceuticals, Inc., a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, Inc., a privately held, late-clinical stage pharmaceutical company developing innovative novel drugs addressing major unmet...

CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), announced the completion of a $20 million round in equity financing. The...

Bristol-Myers Squibb Company and Pfizer Inc. announced findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial...

Janssen Pharmaceuticals, Inc. (Janssen) announced new Phase 3 results from EINSTEIN CHOICE showing patients with venous thromboembolism (VTE) taking XARELTO® (rivaroxaban), who received either 10 mg or 20 mg once daily over an extended time...

With the launch of the Edora series, BIOTRONIK brings the highest functionality to its smallest pacemakers as well as cardiac resynchronization therapy pacemakers (CRT-Ps). The new devices are equipped with features geared towards improving...

Ridgefield, CT, March 19, 2017 – Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial fibrillation (AFib) patients undergoing catheter ablation....

Medtronic plc announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has approved coverage for the Micra® Transcatheter Pacing System (TPS). This decision, effective immediately, follows the approval of two studies...

ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced that the company’s Hospital Wearable Defibrillator (HWD) has been granted premarket approval (PMA) by the U.S....

ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, announced that the 175th patient has been randomized into GENETIC-AF, a...